Back to search results

OBT076 for Recurrent/Metastatic CD205+ Solid Tumors

This study is testing an investigational drug called OBT076 for people aged 18 and older with recurrent (cancer that has come back) or metastatic (cancer that has spread) solid tumors. These are tumors for which standard treatments are no longer working or available. OBT076 is an antibody-drug conjugate (ADC), which means it combines an antibody designed to target cancer cells with a powerful anti-cancer drug. The antibody in OBT076 specifically targets a protein called CD205 found on cancer cells, delivering the drug directly to them. The main goals of this study are to understand the safety of OBT076, including any side effects and dose-limiting toxicities (serious side effects that prevent increasing the dose). This study plans to enroll about 200 participants.

Study design
This is an open-label, Phase I study, meaning both you and your doctors will know you are receiving OBT076. It involves different parts, including dose escalation and expansion, and will enroll approximately 200 participants.
What's involved
You would receive OBT076 as an intravenous (IV) infusion every 3 weeks. The study involves screening, treatment, and follow-up periods, but the exact number of visits or procedures is not specified.
Compensation
Not stated in the trial record.
Follow-up
The primary safety endpoints are measured at 1 year after starting the study.

AI-generated from the public study record. Only the study team can confirm whether you're eligible — confirm details with them before making decisions.

NCT04064359

Safety and Preliminary Efficacy of OBT076 in Recurrent/Metastatic CD205+ Solid Tumors

Recruiting
PHASE1Ages 18+InterventionalTreatment
Oxford BioTherapeutics Ltd
~200 participants
Updated 2025-09-16 on ClinicalTrials.gov
What's tested:OBT076, a CD205-directed antibody-drug conjugate

At a glance

Recruiting sites
13 of 27 listed sites are recruiting right now
RecruitingSuspended, closed, or not yet open
What they're measuring
Incidence of Adverse Events (AEs) as assessed by NCI CTCAE (Version 5)
Measured over 1 year
+1 more outcome measured

Conditions

Solid Tumor

Explore related trials

Breast CarcinomaLung Non-Small Cell CarcinomaSolid NeoplasmUrothelial CarcinomaCD205 Antigen

Where it's being run

27 sites across 14 states
France7
Greece4
Spain3
California2
Belgium2
Arizona1
Florida1
Iowa1

Who to contact

Medical Monitor
[email protected]
+44 (0)1235 861770
Email the study team

Opens a ready-to-send draft in your own email app — review before sending.

Do you actually qualify for this trial?

Add a private profile and we'll compare every criterion below against your situation — and tell you which ones are met, uncertain, or excluding.

Check eligibility for this trial ~2 min · HIPAA-protected · delete anytime
Eligibility criteria

Exclusion

ANC of \<1.5 x 109 cells/L
Platelets of \< 100 x 109 cells/L
Hemoglobin of \< 9 g/dL 6. Patients who received G-CSF in the 14 days prior to Cycle 1 Day 1 7. Patients who had febrile neutropenia during the previous line of therapy or during the last line of therapy containing cytotoxic chemotherapy. 8. Patients who are primary refractory to anti-PD-(L)1 directed therapy. 9. Patients with NSCLC and more than 2 prior lines of systemic anti-cancer therapy in the locally-advanced/metastatic disease setting; and who received more than one prior line of cytotoxic chemotherapy in the locally-advanced/metastatic setting. 10. Patients with urothelial cancer who received more than 3 prior lines of systemic anti cancer therapy in locally-advanced/metastatic disease setting. Prior neoadjuvant or adjuvanttherapy is not counted.

What this trial measures

  • Incidence of Adverse Events (AEs) as assessed by NCI CTCAE (Version 5)1 year

    Assess incidence of all AEs by NCI CTCAE (Version 5) grades 1-5

  • Percentage of subjects with dose-limiting toxicities (DLTs) as assessed by NCI CTCAE (Version 5)1 year

    DLTs defined by NCI CTCAE (Version 5) grades 3-4, with exceptions for duration